基本信息
成交结构
基于近 60 日量价数据观察资金强弱。
交易信号历史
按时间回看该股票被模型捕捉到的买点信号。
| 信号日期 | 模型来源 | 评分/强度 | 信号价格 | 止损价 | 止盈价 | 当前表现 | 操作结论 |
|---|---|---|---|---|---|---|---|
| 2026-05-12 | 动量强势 | +77.1% | $67.92 | $59.77 | $84.22 | -28.2% | 可买入 |
| 2026-05-11 | 动量强势 | +101.9% | $69.33 | $61.01 | $85.97 | -29.7% | 可买入 |
| 2026-05-10 | 动量强势 | +101.9% | $69.33 | $61.01 | $85.97 | -29.7% | 可买入 |
| 2026-05-09 | 动量强势 | +101.9% | $69.33 | $61.01 | $85.97 | -29.7% | 可买入 |
| 2026-05-08 | 动量强势 | +95.7% | $66.96 | $58.92 | $83.03 | -27.2% | 可买入 |
| 2026-05-07 | 动量强势 | +96.5% | $67.36 | $59.28 | $83.53 | -27.6% | 可买入 |
| 2026-05-06 | 动量强势 | +104.2% | $69.28 | $60.97 | $85.91 | -29.6% | 可买入 |
公司简介
AnaptysBio, Inc. discovers and out-licenses therapeutic bodies in the United States. The company manages financial collaborations for Jemperli, a PD-1 antagonist for various solid tumor indications; and Quimilza, an IL-36R antagonist mAb, which has completed two registration-enabling global Phase 3 trials, and GEMINI-1 and GEMINI-2, evaluating the safety and efficacy of Quimilza in patients with generalized pustular psoriasis. It has a collaboration and exclusive license agreement with GSK plc to develop Jemperli as a monotherapy; and an exclusive license agreement with Vanda Pharmaceuticals Inc. for the development and commercialization of Quimilza. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was incorporated in 2005 and is based in San Diego, California.